HDAC9 and cancer: As new drug options are considered for cancer treatment, it is of utmost importance to keep in mind that in patients with FA, the characteristics that account for specific toxicity of HDAC inhibitors in cancer cells are present in all of the patient’s cells, rendering them more susceptible to toxicity.